Trial Outcomes & Findings for Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia (NCT NCT00611806)
NCT ID: NCT00611806
Last Updated: 2014-08-19
Results Overview
The change from baseline on the Positive and Negative Syndrome Scale (PANSS).The PANNS has three subscales: positive (score range 7-49), negative (score range 7-49), and general psychopathology (score range 16-112). The PANSS positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7, representing positive symptoms of schizophrenia. The PANSS negative symptom subscale is comprised of 7 items rated on a scale of 1-7 representing the negative symptoms of schizophrenia, and the general psychopathology subscale is comprised of 16 items rated on a scale of 1-7 representing symptoms of general psychopathology in mental illness. The total score was computed by adding all the items on the sub-scale together. Scores reported are change in symptoms per week, relative to baseline. A negative score represents a decrease in total PANSS score per week, whereas a positive score represents an increase in total PANSS score per week.
COMPLETED
PHASE4
140 participants
Baseline vs. Week 16
2014-08-19
Participant Flow
189 Participants were screened for enrollment, but 49 were excluded. 40 were ineligible, 2 withdrew consent, 1 terminated because of an adverse event, and 6 were terminated because of study visit noncompliance.
Participant milestones
| Measure |
Folate With B12
Participants will take folic acid plus B12 for 18 weeks.
Folic Acid: Folic acid 2mg po daily
B12: B12 400 micrograms po daily
|
Placebo
Participants will take placebo for 18 weeks.
Placebo: 1 capsule po daily
|
|---|---|---|
|
Overall Study
STARTED
|
94
|
46
|
|
Overall Study
COMPLETED
|
78
|
43
|
|
Overall Study
NOT COMPLETED
|
16
|
3
|
Reasons for withdrawal
| Measure |
Folate With B12
Participants will take folic acid plus B12 for 18 weeks.
Folic Acid: Folic acid 2mg po daily
B12: B12 400 micrograms po daily
|
Placebo
Participants will take placebo for 18 weeks.
Placebo: 1 capsule po daily
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
8
|
2
|
|
Overall Study
Adverse Event
|
2
|
1
|
|
Overall Study
Lost to Follow-up
|
6
|
0
|
Baseline Characteristics
Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia
Baseline characteristics by cohort
| Measure |
Folate With B12
n=94 Participants
Participants will take folic acid plus B12 for 18 weeks.
Folic Acid: Folic acid 2mg po daily
B12: B12 400 micrograms po daily
|
Placebo
n=46 Participants
Participants will take placebo for 18 weeks.
Placebo: 1 capsule po daily
|
Total
n=140 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
45.3 Years
STANDARD_DEVIATION 1.1 • n=99 Participants
|
45.9 Years
STANDARD_DEVIATION 1.6 • n=107 Participants
|
45.6 Years
STANDARD_DEVIATION 1.35 • n=206 Participants
|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
94 Participants
n=99 Participants
|
46 Participants
n=107 Participants
|
140 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Sex: Female, Male
Female
|
28 Participants
n=99 Participants
|
32 Participants
n=107 Participants
|
60 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
66 Participants
n=99 Participants
|
14 Participants
n=107 Participants
|
80 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
94 participants
n=99 Participants
|
46 participants
n=107 Participants
|
140 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline vs. Week 16Population: Participants analyzed were those who completed at least 1 post-baseline visit or more (n = 135). 120 participants completed the study to the week 16 endpoint; however, 15 participants did not complete the entire 16 weeks, but completed at least one post-baseline study visit where the PANSS assessment was performed.
The change from baseline on the Positive and Negative Syndrome Scale (PANSS).The PANNS has three subscales: positive (score range 7-49), negative (score range 7-49), and general psychopathology (score range 16-112). The PANSS positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7, representing positive symptoms of schizophrenia. The PANSS negative symptom subscale is comprised of 7 items rated on a scale of 1-7 representing the negative symptoms of schizophrenia, and the general psychopathology subscale is comprised of 16 items rated on a scale of 1-7 representing symptoms of general psychopathology in mental illness. The total score was computed by adding all the items on the sub-scale together. Scores reported are change in symptoms per week, relative to baseline. A negative score represents a decrease in total PANSS score per week, whereas a positive score represents an increase in total PANSS score per week.
Outcome measures
| Measure |
Folate With B12
n=89 Participants
Participants will take folic acid plus B12 for 18 weeks.
Folic Acid: Folic acid 2mg po daily
B12: B12 400 micrograms po daily
|
Placebo
n=46 Participants
Participants will take placebo for 18 weeks.
Placebo: 1 capsule po daily
|
|---|---|---|
|
Positive and Negative Syndrome Scale (PANSS)
|
-.21 units on a scale
Interval -0.35 to -0.07
|
-.22 units on a scale
Interval -0.42 to -0.03
|
SECONDARY outcome
Timeframe: Measured at Week 16Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline vs. Week 16Population: Participants analyzed were those who completed at least 1 post-baseline visit or more (n = 135). 120 participants completed the study to the week 16 endpoint; however, 15 participants did not complete the entire 16 weeks, but completed at least one post-baseline study visit where the PANSS assessment was performed.
The change from baseline on the positive symptom sub-scale of the Positive and Negative Syndrome Scale (PANSS). Total PANSS positive symptom sub-scale scores range from 7-49. The PANSS positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. A score of one on each item 1 absent, 2 is minimal, 3 is mild, 4 is moderate, 5 is moderately severe, 6 is severe, and 7 is extreme. The total score was computed by adding all the items on the sub-scale together. Scores reported are change in symptoms per week, relative to baseline. A negative score represents a decrease in total PANSS score per week, whereas a positive score represents an increase in total PANSS score per week.
Outcome measures
| Measure |
Folate With B12
n=89 Participants
Participants will take folic acid plus B12 for 18 weeks.
Folic Acid: Folic acid 2mg po daily
B12: B12 400 micrograms po daily
|
Placebo
n=46 Participants
Participants will take placebo for 18 weeks.
Placebo: 1 capsule po daily
|
|---|---|---|
|
Positive Sub Scale of the Positive and Negative Syndrome Scale (PANSS)
|
-.06 units on a scale
Interval -0.12 to -0.01
|
-.04 units on a scale
Interval -0.11 to 0.03
|
SECONDARY outcome
Timeframe: Baseline vs. Week 16Population: Participants analyzed were those who completed at least 1 post-baseline visit or more (n = 135). 120 participants completed the study to the week 16 endpoint; however, 15 participants did not complete the entire 16 weeks, but completed at least one post-baseline study visit where the SANS assessment was performed.
The change from baseline on the scale for the assessment of negative symptoms (SANS) total score. Total SANS scores range from 0-100. The SANS is comprised of 5 subscores: Affective Flattening or Blunting (score range 0-35), Alogia (score range 0-20), Avolition-Apathy (score range 0-15), Anhedonia-Asociality (score range 0-20), and Attention (0-10). For each scale, the higher the score the more prominent the negative symptoms were. The total score was computed by adding all the sub-scale total scores. Scores reported are change in symptoms per week, relative to baseline. A negative score represents a decrease in total SANS score per week, whereas a positive score represents an increase in total SANS score per week.
Outcome measures
| Measure |
Folate With B12
n=89 Participants
Participants will take folic acid plus B12 for 18 weeks.
Folic Acid: Folic acid 2mg po daily
B12: B12 400 micrograms po daily
|
Placebo
n=46 Participants
Participants will take placebo for 18 weeks.
Placebo: 1 capsule po daily
|
|---|---|---|
|
Scale for Assessment of Negative Symptoms (SANS)
|
-.19 units on a scale
Interval -0.35 to -0.03
|
.02 units on a scale
Interval -0.21 to 0.24
|
SECONDARY outcome
Timeframe: Baseline vs. Week 16Population: Participants analyzed were those who completed at least 1 post-baseline visit or more (n = 135) and agreed to the DNA blood draw (n = 120).
The change from baseline on the Positive and Negative Syndrome Scale (PANSS) (including FOLH1, MTHRF, MTR, and COMT genotype simultaneously into a linear mixed model).The PANNS has three sub-scales: positive (score range 7-49), negative (score range 7-49), and general psychopathology (score range 16-112). The PANSS negative and positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7 representing the negative and positive symptoms of schizophrenia, respectively, and the general psychopathology sub-scale is comprised of 16 items rated on a scale of 1-7 representing symptoms of general psychopathology in mental illness. The total score was computed by adding all the items on the sub-scale together. Scores reported are change in symptoms per week, relative to baseline. A negative score represents a decrease in total PANSS score per week, whereas a positive score represents an increase in total PANSS score per week.
Outcome measures
| Measure |
Folate With B12
n=79 Participants
Participants will take folic acid plus B12 for 18 weeks.
Folic Acid: Folic acid 2mg po daily
B12: B12 400 micrograms po daily
|
Placebo
n=41 Participants
Participants will take placebo for 18 weeks.
Placebo: 1 capsule po daily
|
|---|---|---|
|
Positive and Negative Syndrome Scale (PANSS) and FOLH1, MTHRF, MTR, and COMT Genotype
|
-.21 units on a scale
Interval -0.35 to -0.07
|
-.1 units on a scale
Interval -0.31 to 0.11
|
SECONDARY outcome
Timeframe: Measured at Week 16Outcome measures
Outcome data not reported
Adverse Events
Folate With B12
Placebo
Serious adverse events
| Measure |
Folate With B12
n=94 participants at risk
Participants will take folic acid plus B12 for 18 weeks.
Folic Acid: Folic acid 2mg po daily
B12: B12 400 micrograms po daily
|
Placebo
n=46 participants at risk
Participants will take placebo for 18 weeks.
Placebo: 1 capsule po daily
|
|---|---|---|
|
Psychiatric disorders
Hospitalization due to worsening psychosis
|
1.1%
1/94 • Number of events 2
|
2.2%
1/46 • Number of events 2
|
|
Gastrointestinal disorders
Cholelithiasis
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Nervous system disorders
Body Numbness
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Psychiatric disorders
Suicidal Tendency
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Eye disorders
Vision Decreased
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Nervous system disorders
Brain Tumor
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Skin and subcutaneous tissue disorders
Irritation of Skin
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
Other adverse events
| Measure |
Folate With B12
n=94 participants at risk
Participants will take folic acid plus B12 for 18 weeks.
Folic Acid: Folic acid 2mg po daily
B12: B12 400 micrograms po daily
|
Placebo
n=46 participants at risk
Participants will take placebo for 18 weeks.
Placebo: 1 capsule po daily
|
|---|---|---|
|
Nervous system disorders
Constipation
|
2.1%
2/94 • Number of events 2
|
0.00%
0/46
|
|
Cardiac disorders
Tachycardia
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Endocrine disorders
Hypoglycemia
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Gastrointestinal disorders
Cholelithiasis
|
1.1%
1/94 • Number of events 2
|
0.00%
0/46
|
|
Gastrointestinal disorders
Dirrhea
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Gastrointestinal disorders
Dry Mouth
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Renal and urinary disorders
Enuresis
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Nervous system disorders
Numbness
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Psychiatric disorders
Delusions
|
0.00%
0/94
|
2.2%
1/46 • Number of events 2
|
|
Nervous system disorders
Dizziness
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Nervous system disorders
Injury
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Nervous system disorders
Insomnia
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Psychiatric disorders
Manic Psychosis
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Nervous system disorders
Muscle Spasm
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Psychiatric disorders
Psychosis
|
3.2%
3/94 • Number of events 3
|
2.2%
1/46 • Number of events 1
|
|
Nervous system disorders
Somnolence
|
1.1%
1/94 • Number of events 1
|
2.2%
1/46 • Number of events 1
|
|
Psychiatric disorders
Suicidal Tendency
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
General disorders
Back Pain
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
General disorders
Chest Pain
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
General disorders
Malaise
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Eye disorders
Eye Blood Shot
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Eye disorders
Vision Decreased
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Respiratory, thoracic and mediastinal disorders
Asthema
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Nervous system disorders
Brain Tumor
|
0.00%
0/94
|
2.2%
1/46 • Number of events 1
|
|
Infections and infestations
Infection
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
General disorders
Laboratory Test Abnormality
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Skin and subcutaneous tissue disorders
Irritation of Skin
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Skin and subcutaneous tissue disorders
Rash
|
1.1%
1/94 • Number of events 1
|
0.00%
0/46
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/94
|
4.3%
2/46 • Number of events 2
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place